https://www.taxtmi.com/news?id=53840 Hua Medicine assumed full commercialization of HuaTangNing, recognized a one time release of previously deferred income after terminating the exclusive promotion agreement, and reported doubled prescription volumes and net sales aided by NRDL reimbursement expansion, improved gross margins, reduced selling expense ratio, and a move toward sustained profitability; concurrently, the company advanced real world and clinical studies, filed a Hong Kong registration for dorzagliatin 75 mg, and continued R&D and business development for combination products and next generation GKAs. en-us Thu, 28 Aug 2025 16:16:03 +0530 Thu, 28 Aug 2025 16:16:03 +0530 TaxTMI RSS Generator https://www.taxtmi.com/news?id=53840 Hua Medicine assumed full commercialization of HuaTangNing, recognized a one time release of previously deferred income after terminating the exclusive promotion agreement, and reported doubled prescription volumes and net sales aided by NRDL reimbursement expansion, improved gross margins, reduced selling expense ratio, and a move toward sustained profitability; concurrently, the company advanced real world and clinical studies, filed a Hong Kong registration for dorzagliatin 75 mg, and continued R&D and business development for combination products and next generation GKAs. News - Thu, 28 Aug 2025 16:16:03 +0530 https://www.taxtmi.com/news?id=53840